Top

Published in:

01-10-2009 | Original Paper

Family history of various cancers and pancreatic cancer mortality in a large cohort

Authors: Eric J. Jacobs, Carmen Rodriguez, Christina C. Newton, Elizabeth B. Bain, Alpa V. Patel, Heather Spencer Feigelson, Michael J. Thun, Eugenia E. Calle

Published in: Cancer Causes & Control | Issue 8/2009

Abstract

A family history of pancreatic cancer is associated with increased risk of pancreatic cancer, but uncertainty remains about the magnitude of this association, whether it varies by age or smoking and whether a family history of other cancers may also be associated with increased risk. We examined family history of 14 cancers and pancreatic cancer mortality among ~1.1 million men and women in Cancer Prevention Study-II (CPS-II). CPS-II participants completed a questionnaire at enrollment in 1982. During follow-up through 2006, there were 7,306 pancreatic cancer deaths. A family history of pancreatic cancer in a parent or sibling was associated with pancreatic cancer mortality [multivariable adjusted rate ratio (RR) = 1.66, 95% confidence interval (CI) 1.43–1.94]. This association was stronger among participants aged under 60 (RR = 2.89, 95% CI 1.67–5.02) than among participants aged 60 or older (RR = 1.61, 95% CI 1.37–1.88). Weaker associations were observed for family history of stomach cancer (RR = 1.23, 95% CI 1.11–1.37), liver cancer (RR = 1.25, 95% CI 1.10–1.43), and colorectal cancer (RR = 1.12, 95% CI 1.01–1.23). Results from this large prospective study indicate family history of pancreatic cancer is associated with a moderate increase in risk of pancreatic cancer, and also identify associations with the family history of certain other cancers which may be useful in generating hypotheses about shared risk factors.

Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86(21):1600–1608. doi:10.1093/jnci/86.21.1600 PubMedCrossRef

Coughlin SS, Calle EE, Patel AV, Thun MJ (2000) Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 11:915–923. doi:10.1023/A:1026580131793 PubMedCrossRef

Hemminki K, Li X (2003) Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 103(4):525–530. doi:10.1002/ijc.10863 PubMedCrossRef

Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S et al (2004) Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 1(3):e65. doi:10.1371/journal.pmed.0010065 PubMedCrossRef

Fernandez E, La Vecchia C, D’Avanzo B, Negri E, Franceschi S (1994) Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 3(3):209–212PubMed

Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM et al (1999) Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80(11):1830–1837. doi:10.1038/sj.bjc.6690607 PubMedCrossRef

Schenk M, Schwartz AG, O’Neal E, Kinnard M, Greenson JK, Fryzek JP et al (2001) Familial risk of pancreatic cancer. J Natl Cancer Inst 93(8):640–644. doi:10.1093/jnci/93.8.640 PubMedCrossRef

Ghadirian P, Liu G, Gallinger S, Schmocker B, Paradis AJ, Lal G et al (2002) Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas. Int J Cancer 97(6):807–810. doi:10.1002/ijc.10123 PubMedCrossRef

McWilliams RR, Rabe KG, Olswold C, De Andrade M, Petersen GM (2005) Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 104(2):388–394. doi:10.1002/cncr.21166 PubMedCrossRef

10.

Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, Pisters PW et al (2007) Risk factors for pancreatic cancer: case–control study. Am J Gastroenterol 102(12):2696–2707. doi:10.1111/j.1572-0241.2007.01510.x PubMedCrossRef

11.

Del Chiaro M, Zerbi A, Falconi M, Bertacca L, Polese M, Sartori N et al (2007) Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology 7(5–6):459–469. doi:10.1159/000108963 PubMedCrossRef

12.

Poole CA, Byers T, Calle EE, Bondy J, Fain P, Rodriguez C (1999) Influence of a family history of cancer within and across multiple sites on patterns of cancer mortality risk for women. Am J Epidemiol 149(5):454–462PubMed

13.

Habbe N, Langer P, Sina-Frey M, Bartsch DK (2006) Familial pancreatic cancer syndromes. Endocrinol Metab Clin North Am 35(2):417–430. doi:10.1016/j.ecl.2006.02.016 PubMedCrossRef

14.

Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16(2):342–346. doi:10.1158/1055-9965.EPI-06-0783 PubMedCrossRef

15.

Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne SJ et al (2008) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7(2):163–172. doi:10.1007/s10689-007-9164-6 PubMedCrossRef

16.

Stellman SD, Garfinkel L (1986) Smoking habits and tar levels in a new American Cancer Society prospective study of 1.2 million men and women. J Natl Cancer Inst 76:1057–1063PubMed

17.

Calle EE, Terrell DD (1993) Utility of the national death index for ascertainment of mortality among Cancer Prevention Study II participants. Am J Epidemiol 137:235–241PubMed

18.

World Health Organization (1977) International classification of diseases: manual of the international statistical classification of diseases, injuries, and causes of death, vol 1. World Health Organization, Geneva (Switzerland) 9th Revision

19.

Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ (2005) Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14(7):1766–1773. doi:10.1158/1055-9965.EPI-05-0120 PubMedCrossRef

20.

Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc (B) 34:187–220

21.

Kleinbaum DG (1996) Survival analysis: a self-learning text. Springer, New York

22.

Hemminki K, Li X (2001) Familial colorectal adenocarcinoma and hereditary nonpolyposis colorectal cancer: a nationwide epidemiological study from Sweden. Br J Cancer 84:969–974. doi:10.1054/bjoc.2000.1718 PubMedCrossRef

23.

Raymond J, Thiberg JM, Chevalier C, Kalach N, Bergeret M, Labigne A et al (2004) Genetic and transmission analysis of Helicobacter pylori strains within a family. Emerg Infect Dis 10(10):1816–1821PubMed

24.

Miyazaki M, Kato M, Takata T, Une H (2002) Intrafamilial transmission of Helicobacter pylori: the association between a parent and an offspring with respect to the presence of anti-CagA antibody. J Infect Chemother 8(1):70–75PubMed

25.

Helicobacter and Cancer Collaborative Group (2001) Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49(3):347–353CrossRef

26.

Raderer M, Wrba F, Kornek G, Maca T, Koller DY, Weinlaender G et al (1998) Association between Helicobacter pylori infection and pancreatic cancer. Oncology 55(1):16–19. doi:10.1159/000011830 PubMedCrossRef

27.

Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J et al (2001) Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 93(12):937–941. doi:10.1093/jnci/93.12.937 PubMedCrossRef

28.

de Martel C, Llosa AE, Friedman GD, Vogelman JH, Orentreich N, Stolzenberg-Solomon RZ et al (2008) Helicobacter pylori infection and development of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 17(5):1188–1194. doi:10.1158/1055-9965.EPI-08-0185 PubMedCrossRef

29.

Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218. doi:10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L PubMedCrossRef

30.

Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L et al (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60(5):1079–1084PubMed

31.

Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G et al (1996) High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 56(16):3663–3665PubMed

32.

Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA et al (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60(2):409–416PubMed

33.

Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV et al (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13(1):117–119. doi:10.1038/ng0596-117 PubMedCrossRef

34.

Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. Jama 292(12):1480–1489. doi:10.1001/jama.292.12.1480 PubMedCrossRef

35.

Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML et al (2002) The American Cancer Society cancer prevention study II nutrition cohort—rationale, study design and baseline characteristics. Cancer 94:2490–2501. doi:10.1002/cncr.101970 PubMedCrossRef

36.

Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L et al (eds) (2002) SEER Cancer Statistics Review, 1973–1999. National Cancer Institute, Bethesda

Title: Family history of various cancers and pancreatic cancer mortality in a large cohort
Authors: Eric J. Jacobs
Carmen Rodriguez
Christina C. Newton
Elizabeth B. Bain
Alpa V. Patel
Heather Spencer Feigelson
Michael J. Thun
Eugenia E. Calle
Publication date: 01-10-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 8/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9339-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2009

Physical activity in adolescence and testicular germ cell cancer risk

Response to Dr. Costellos’ submission entitled “Re: Vitamin and mineral use and risk of prostate cancer: the case–control surveillance: Zhang et al. Cancer Causes Control. 2008 Dec 18. [Epub ahead of print]”

Access to mammography screening in a large urban population: a multi-level analysis

Ionizing radiation: a risk factor for mesothelioma

Reply to: Dr. Peter Morfeld’s Letter to the Editor (Manuscript Number: CACO2009): “Comment on Lacasse Y, Martin S, Gagne D, Lakhal L (2009) Dose–response meta-analysis of silica and lung cancer. Cancer Causes and Control; [e-pub ahead of print] doi: 10.1007/s10552-009-9296-0”

Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women—implications for vaccination

Keynote webinar | Spotlight on antibody–drug conjugates in cancer